Abstract
Corticotropin, adrenal cortical steroids, alkylating agents, and antimetabolites are being used to treat multiple sclerosis (MS). The benefits of these substances must be carefully weighed against the risks. While the steroids appear to improve neurologic function lost in acute relapses, they do not affect progression. They may increase the frequency of relapses or predispose patients to earlier relapses than expected during the natural course of the illness. The alkylating agent cyclophosphamide appears to temporarily improve neurologic function, decrease spinal fluid immunoglobulin, and prevent progression. Cancer of the bladder and leukemia are serious long-term risks in a young population. Chlorambucil appears relatively ineffective and leukemogenic. Relapse rate and progression are most likely ameliorated by several years' treatment with the antimetabolite azathioprine. The long-term risks to the patient and his or her children are unknown. Controlled clinical trials of 5 to 10 years' duration with even longer follow-up will be necessary to delineate risk and benefit. No factors that will predict response to the drugs are known. Since the immunosuppressive drugs will probably be required for life in many patients, we may be faced with a choice between control of symptoms and signs at age 30 or increased risk of cancer at age 60.
- © 1980 by the American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
